Bryant RV - Search Results

1

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Peyrin-Biroulet L, et al. Among authors: bryant rv. Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25. Am J Gastroenterol. 2015. PMID: 26303131 Review.

2

Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status.

Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM. Bryant RV, et al. J Gastroenterol Hepatol. 2011 May;26(5):916-23. doi: 10.1111/j.1440-1746.2011.06624.x. J Gastroenterol Hepatol. 2011. PMID: 21214889

3

Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk?

Bryant RV, Jairath V, Curry N, Travis SP. Bryant RV, et al. J Crohns Colitis. 2014 Feb;8(2):166-71. doi: 10.1016/j.crohns.2013.09.007. Epub 2013 Oct 4. J Crohns Colitis. 2014. PMID: 24095288

4

Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.

Bryant RV, Winer S, Travis SP, Riddell RH. Bryant RV, et al. J Crohns Colitis. 2014 Dec;8(12):1582-97. doi: 10.1016/j.crohns.2014.08.011. Epub 2014 Sep 27. J Crohns Colitis. 2014. PMID: 25267173 Review.

5

Conventional drug therapy for inflammatory bowel disease.

Bryant RV, Brain O, Travis SP. Bryant RV, et al. Scand J Gastroenterol. 2015 Jan;50(1):90-112. doi: 10.3109/00365521.2014.968864. Scand J Gastroenterol. 2015. PMID: 25523560 Review.

6

Introducing vedolizumab to clinical practice: who, when, and how?

Bryant RV, Sandborn WJ, Travis SP. Bryant RV, et al. J Crohns Colitis. 2015 Apr;9(4):356-66. doi: 10.1093/ecco-jcc/jjv033. Epub 2015 Feb 16. J Crohns Colitis. 2015. PMID: 25687206 Review.

7

Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease.

Bryant RV, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, Lim A, Bartholomeusz FD, Andrews JM. Bryant RV, et al. Aliment Pharmacol Ther. 2015 May;41(9):895-906. doi: 10.1111/apt.13156. Epub 2015 Mar 5. Aliment Pharmacol Ther. 2015. PMID: 25753216

8

Response to Villanacci et. al.

Bryant RV, Winer S, Travis SP, Riddell RH. Bryant RV, et al. J Crohns Colitis. 2015 May;9(5):429. doi: 10.1093/ecco-jcc/jjv046. Epub 2015 Mar 11. J Crohns Colitis. 2015. PMID: 25761770 No abstract available.

9

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Bryant RV, et al. Gut. 2016 Mar;65(3):408-14. doi: 10.1136/gutjnl-2015-309598. Epub 2015 May 18. Gut. 2016. PMID: 25986946

10

Current best practice for disease activity assessment in IBD.

Walsh AJ, Bryant RV, Travis SP. Walsh AJ, et al. Among authors: bryant rv. Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):567-79. doi: 10.1038/nrgastro.2016.128. Epub 2016 Sep 1. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27580684 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters